Duyuru • Apr 01
Stemtech Corporation announced delayed annual 10-K filing On 03/31/2026, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Jan 07
Stemtech Corporation Appoints Dr. Lizette Leos, MD as Chief Scientific Officer Stemtech Corporation appointed Dr. Lizette Leos, MD to Chief Scientific Officer. Dr. Leos has been with Stemtech since 2017 and has significantly contributed to the science, creation and development, including education of stemceuticals all-natural, plant-based, non-GMO nutritional supplements designed to support the body's own regenerative processes. Promoting her to the role of Chief Scientific Officer recognizes both her longstanding impact and leadership in the development of new evidence-driven innovations. Her scientific knowledge of products, ability to translate complex biology into practical education, and commitment to Stemtech's non-chemical approaches to cellular health have been instrumental to Stemtech's growth, with focus on anti-aging and longevity. As Chief Scientific Officer, Dr. Leos will lead Stemtech Corporation's global scientific validation, education and regulatory alignment for Stemtech's recently announced joint ventures in Stemtech HealthSciences India Pvt Ltd. and the GCC (Gulf Cooperation Council countries of the United Arab Emirates, Bahrain, Saudi Arabia, Qatar, Kuwait and Oman). In addition, Dr. Leos will also support Stemtech Asia (Hong Kong) for business in the Peoples Republic of China. Dr. Leos is a medical doctor based in Guadalajara, Mexico, and has worked with Stemtech since 2017. She holds a Master's Degree in Aesthetic and Anti-Aging Medicine from the Instituto Mexicano de Medicina Antienvejecimiento y Esttica (IMMAE) (2023), postgraduate training in Molecular Nutrition and Smart Food Design from Tecnológico de Monterrey, Campus Guadalajara (2018), and earned her Medical Degree from Universidad Guadalajara Lamar, with her professional title issued by the Universidad de Guadalajara (2007). With over 10 years of experience in regenerative medicine, nutrigenomics, cellular health, and aesthetic medicine, Dr. Leos has served on the Stemtech Life Sciences Advisory Board, where she has designed global educational programs, scientific symposiums, and evidence-based clinical and educational protocols. She brings deep expertise in scientific and medical communication, clinical protocol development, and cross-functional collaboration across scientific, regulatory, and commercial teams. Fluent in English and Spanish, she contributes significant cross-cultural leadership to Stemtech's international operations. Duyuru • Nov 15
Stemtech Corporation announced delayed 10-Q filing On 11/14/2025, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Aug 15
Stemtech Corporation announced delayed 10-Q filing On 08/14/2025, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Apr 15
Stemtech Corporation Announces CFO Changes On April 11, 2025, James Cardwell resigned his position as CFO of Stemtech Corporation. At the same time the Board appointed Shrilakshmi Vadlapatla as CFO. Ms. Vadlapatla, 40, is a seasoned boutique accountant with years of experience in audit compliance, SEC reporting, internal controls, Sarbanes-Oxley compliance and strategic financial management. With a strong background in GAAP and IFRS principles, earnings analysis, and external audits, she provides expertise in risk assessment, Sarbanes-Oxley compliance, and the development of robust financial policies and procedures. Ms. Vadlapatla holds a Bachelor of Commerce in Accounting from Osmania University, (India), 2005. Duyuru • Apr 01
Stemtech Corporation announced delayed annual 10-K filing On 03/31/2025, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Dec 02
Stemtech Corporation signed a letter of intent to acquire Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction. Stemtech Corporation signed a letter of intent to acquire Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction on November 10, 2024. The proposal suggests that Eevia buy the Stemtech's assets (“Stemtech Assets”) and issue new shares to the Stemtech, providing that Stemtech will own c. 85% of the new outstanding shares after such a transaction. Stemtech's valuation would be approximately $40 million, and the remaining 15% of the shares would value Eevia at approximately $6-7 million. The final valuation, number of shares to be issued, and issue price are subject to negotiation and the due diligence process of both companies. Duyuru • Nov 20
Stemtech Corporation (OTCPK:STEK) entered into an agreement in principle to acquire SEACRET Direct, LLC. Stemtech Corporation (OTCPK:STEK) entered into an agreement in principle to acquire SEACRET Direct, LLC on November 20, 2024. The proposed merger is expected to be for all stock consideration and is subject to conditions to closing, including required board and shareholder approvals, the finalization of definitive agreements, the audit of VIÁGO financial statements and other customary conditions. Stemtech and VIÁGO expect to finalize the definitive agreements for the merger soon. Duyuru • Nov 15
Stemtech Corporation announced delayed 10-Q filing On 11/14/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Aug 23
Stemtech Corporation Announces the Launch of StemPets Stemtech Corporation announced an exciting new product line into the pet health care industry with the launch of StemPets™?. This revolutionary product is designed to provide substantial health benefits to dogs, cats, and other beloved pets, tapping into the $303 billion pet health care market. Recognizing the profound love humans hold for their pets and the significant expenses they incur to keep them healthy, Stemtech has developed StemPets. This natural stemceutical product promises to offer amazing health benefits to pets as human products have provided for nearly two decades. Stemtech has negotiated an exclusive distribution agreement for StemPets, ensuring that this novel product will be available through established channels. Over the past year, company has tested StemPets with a variety of pet owners, receiving overwhelmingly positive feedback regarding its natural taste and health benefits. This expansion into the pet health care industry also presents a significant opportunity for younger distributors of products, including Gen X individuals under 40 who may not yet prioritize human stem cell health but are enthusiastic about superior health products for their pets. Stemtech's dedication to scientific innovation and health continues with the introduction of StemPets, marking a new chapter in mission to improve lives, both human and animal. Duyuru • Aug 15
Stemtech Corporation announced delayed 10-Q filing On 08/14/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • May 17
Stemtech Corporation announced delayed 10-Q filing On 05/15/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Mar 30
Stemtech Corporation announced delayed annual 10-K filing On 03/29/2024, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Nov 15
Stemtech Corporation announced delayed 10-Q filing On 11/14/2023, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Jan 11
Stemtech Corporation Appoints Margie and Mike Mares to Field Advisory Board Stemtech Corporation announced the appointment of Margie and Mike Mares of Stemtech Mexico to Stemtech's Field Advisory Board (FAB). Margie has a degree in Communications and has also worked in the cosmetic industry as a senior executive in the areas of sales, marketing and public relations. Mike has earned a Bachelor of Business Administration and Marketing from UP and a Professional Photographer from NYIP. He has experience in marketing, e-commerce, Community Management and growth of markets and social networks, management and the creation of bots, logistics and finance. Duyuru • Dec 07
Stemtech Corporation Announces Introduction of Cellectone Rapid Renew Stem Cell Peptide Night Cream Stemtech Corporation (Stemtech) announced the introduction of their new CellectOne™ innovative and cutting-edge Skincare line, with the first product being the Rapid Renew Stem Cell Peptide Night Cream. Duyuru • Sep 20
Stemtech Corporation Announces Creation of New Stem Cell Skincare Products Stemtech Corporation announced creation of new stem cell skincare products. Duyuru • Sep 07
Stemtech Corporation Announces Professor Dr. Bankole Johnson Joins Their Life Sciences Advisory Board Stemtech Corporation announced that Professor Dr. Bankole Johnson joins the Stemtech Corporation Life Sciences Advisory Board (LSAB). Forbes Magazine articulated that “Dr. Johnson was a fully-practicing MD by the age of 22, when he became an intensive care doctor. After that, and after completing the necessary schooling, he became an anesthesiologist, and then a psychiatrist. He further pursued higher education with the completion of two more doctorates in addition to his MD, and a Masters Degree in neurological disorders and computational mathematics. While practicing medicine and making discoveries in the areas of psychopharmacology in the treatment of addiction, he rose in academia to become the Alumni Professor and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, followed by a similar role at the University of Maryland where he was Chairman of Psychiatry and Professor of pharmacology, medicine, psychiatry, anatomy, neurobiology, and neurology.” Professor Dr. Bankole Johnson gained national attention for his appearance in the Home Box Office (HBO) 2007 documentary Addiction, which won the Governor’s Award (a special Emmy Award) from the Academy of Television Arts and Sciences. This being the highest award presented by the Academy. He also appeared on the esteemed 2009 CNN special, anchored by Chief Medical Correspondent Dr. Sanjay Gupta, called Addiction: Life on the Edge. Furthermore, Professor Dr. Bankole Johnson is a regular medical correspondent for major network channels in the USA, especially during the COVID-19 pandemic. Presently, Dr. Johnson is the Founder, Executive Chairman, and CEO of Casa Privée, based in Miami, and the Founder and Chief Medical Officer of Adial Pharmaceuticals Inc., a NASDAQ listed company. Professor Dr. Johnson also functions as a Professor of Biomedical Sciences at Larkin University in Miami. Duyuru • Aug 30
Stemtech Corporation (OTCPK:STEK) entered into a letter of intent to acquire Life Factor Research. Stemtech Corporation (OTCPK:STEK) entered into a letter of intent to acquire Life Factor Research on August 29, 2022. Duyuru • Aug 24
Stemtech Corporation Announces Orastem Trademark Registration in Mexico and Introduces New Travel Size Stemtech Corporation announced that OraStem®, Stemtech’s all-natural toothpaste, has been trademarked registered in Mexico. OraStem is composed of fourteen natural, non-GMO, and organic ingredients: powerful antioxidants, botanicals, herbal extracts, CoQ10, vitamins, and natural flavors. Their efficacy and safety for oral health have been supported by dozens of studies published in peer-reviewed journals. Stemtech will also be introducing a new sample /travel size of OraStem soon. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and international markets. Its patented formulas help the release, circulation and migration of the body’s adult stem cells from the bone marrow. Also offered is the OraStem and D-Fuze, an Electro Magnetic Field blocker. Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplemental Health and Education Act (DSHEA). Stemtech has a history of innovation and was the first to market in the category of stem cell nutrition and was recognized four separate times by Inc. 5000 Fastest-Growing Companies list. Stemtech’s primary marketing and distribution channel is through a direct sales structure, which offers supplemental and residual income-earning potential to IBPs.